NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE (ammonium chloride) by Pfizer. Approved for end-stage renal disease.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ammonium chloride 0.9% in normal saline is an injectable electrolyte replacement solution indicated for end-stage renal disease (ESRD) patients. It functions as a systemic acidifying agent and electrolyte supplement administered intravenously. This pre-launch Pfizer product addresses metabolic alkalosis and electrolyte imbalances in a highly specialized renal care setting.
Pre-Launch
Pre-launch stage signals small, focused commercial teams with emphasis on nephrology field personnel, medical affairs, and regulatory expertise rather than large-scale commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.